186 related articles for article (PubMed ID: 33965587)
1. Combined ASBT Inhibitor and FGF15 Treatment Improves Therapeutic Efficacy in Experimental Nonalcoholic Steatohepatitis.
Matye DJ; Wang H; Luo W; Sharp RR; Chen C; Gu L; Jones KL; Ding WX; Friedman JE; Li T
Cell Mol Gastroenterol Hepatol; 2021; 12(3):1001-1019. PubMed ID: 33965587
[TBL] [Abstract][Full Text] [Related]
2. Effects of apical sodium-bile acid transporter inhibitor and obeticholic acid co-treatment in experimental non-alcoholic steatohepatitis.
Matye DJ; Qin X; Hasan MN; Gu L; Clayton YD; Li F; Li T
Liver Res; 2022 Dec; 6(4):276-283. PubMed ID: 36819659
[TBL] [Abstract][Full Text] [Related]
3. Gut-restricted apical sodium-dependent bile acid transporter inhibitor attenuates alcohol-induced liver steatosis and injury in mice.
Matye DJ; Li Y; Chen C; Chao X; Wang H; Ni H; Ding WX; Li T
Alcohol Clin Exp Res; 2021 Jun; 45(6):1188-1199. PubMed ID: 33885179
[TBL] [Abstract][Full Text] [Related]
4. Combining ASBT inhibitor and FGF15 treatments enhances therapeutic efficacy against cholangiopathy in female but not male Cyp2c70 KO mice.
Hasan MN; Chen J; Matye D; Wang H; Luo W; Gu L; Clayton YD; Du Y; Li T
J Lipid Res; 2023 Mar; 64(3):100340. PubMed ID: 36737039
[TBL] [Abstract][Full Text] [Related]
5. TCF7L2 transcriptionally regulates Fgf15 to maintain bile acid and lipid homeostasis through gut-liver crosstalk.
Bhat N; Esteghamat F; Chaube BK; Gunawardhana K; Mani M; Thames C; Jain D; Ginsberg HN; Fernandes-Hernando C; Mani A
FASEB J; 2022 Mar; 36(3):e22185. PubMed ID: 35133032
[TBL] [Abstract][Full Text] [Related]
6. Defective FXR-FGF15 signaling and bile acid homeostasis in cystic fibrosis mice can be restored by the laxative polyethylene glycol.
Bertolini A; van de Peppel IP; Doktorova-Demmin M; Bodewes FAJA; de Jonge H; Bijvelds M; Verkade HJ; Jonker JW
Am J Physiol Gastrointest Liver Physiol; 2019 Mar; 316(3):G404-G411. PubMed ID: 30653340
[TBL] [Abstract][Full Text] [Related]
7. Bile acids contribute to the development of non-alcoholic steatohepatitis in mice.
Gillard J; Clerbaux LA; Nachit M; Sempoux C; Staels B; Bindels LB; Tailleux A; Leclercq IA
JHEP Rep; 2022 Jan; 4(1):100387. PubMed ID: 34825156
[TBL] [Abstract][Full Text] [Related]
8. Aberrant FGFR4 signaling worsens nonalcoholic steatohepatitis in FGF21KO mice.
Yu Y; Shi X; Zheng Q; Wang X; Liu X; Tan M; Lv G; Zhang P; Martin RC; Li Y
Int J Biol Sci; 2021; 17(10):2576-2589. PubMed ID: 34326695
[No Abstract] [Full Text] [Related]
9. The effect of fibroblast growth factor 15 deficiency on the development of high fat diet induced non-alcoholic steatohepatitis.
Schumacher JD; Kong B; Pan Y; Zhan L; Sun R; Aa J; Rizzolo D; Richardson JR; Chen A; Goedken M; Aleksunes LM; Laskin DL; Guo GL
Toxicol Appl Pharmacol; 2017 Sep; 330():1-8. PubMed ID: 28673684
[TBL] [Abstract][Full Text] [Related]
10. Mouse species-specific control of hepatocarcinogenesis and metabolism by FGF19/FGF15.
Zhou M; Luo J; Chen M; Yang H; Learned RM; DePaoli AM; Tian H; Ling L
J Hepatol; 2017 Jun; 66(6):1182-1192. PubMed ID: 28189755
[TBL] [Abstract][Full Text] [Related]
11. Atorvastatin Modulates Bile Acid Homeostasis in Mice with Diet-Induced Nonalcoholic Steatohepatitis.
Lastuvkova H; Faradonbeh FA; Schreiberova J; Hroch M; Mokry J; Faistova H; Nova Z; Hyspler R; Igreja Sa IC; Nachtigal P; Stefela A; Pavek P; Micuda S
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34208774
[TBL] [Abstract][Full Text] [Related]
12. Dysregulated FXR-FGF19 signaling and choline metabolism are associated with gut dysbiosis and hyperplasia in a novel pig model of pediatric NASH.
Hernandez GV; Smith VA; Melnyk M; Burd MA; Sprayberry KA; Edwards MS; Peterson DG; Bennet DC; Fanter RK; Columbus DA; Steibel JP; Glanz H; Immoos C; Rice MS; Santiago-Rodriguez TM; Blank J; VanderKelen JJ; Kitts CL; Piccolo BD; La Frano MR; Burrin DG; Maj M; Manjarin R
Am J Physiol Gastrointest Liver Physiol; 2020 Mar; 318(3):G582-G609. PubMed ID: 32003601
[TBL] [Abstract][Full Text] [Related]
13. Glucose and lipid effects of the ileal apical sodium-dependent bile acid transporter inhibitor GSK2330672: double-blind randomized trials with type 2 diabetes subjects taking metformin.
Nunez DJ; Yao X; Lin J; Walker A; Zuo P; Webster L; Krug-Gourley S; Zamek-Gliszczynski MJ; Gillmor DS; Johnson SL
Diabetes Obes Metab; 2016 Jul; 18(7):654-62. PubMed ID: 26939572
[TBL] [Abstract][Full Text] [Related]
14. Mouse organic solute transporter alpha deficiency alters FGF15 expression and bile acid metabolism.
Lan T; Rao A; Haywood J; Kock ND; Dawson PA
J Hepatol; 2012 Aug; 57(2):359-65. PubMed ID: 22542490
[TBL] [Abstract][Full Text] [Related]
15. An FGF15/19-TFEB regulatory loop controls hepatic cholesterol and bile acid homeostasis.
Wang Y; Gunewardena S; Li F; Matye DJ; Chen C; Chao X; Jung T; Zhang Y; Czerwiński M; Ni HM; Ding WX; Li T
Nat Commun; 2020 Jul; 11(1):3612. PubMed ID: 32681035
[TBL] [Abstract][Full Text] [Related]
16. FXR agonists and FGF15 reduce fecal bile acid excretion in a mouse model of bile acid malabsorption.
Jung D; Inagaki T; Gerard RD; Dawson PA; Kliewer SA; Mangelsdorf DJ; Moschetta A
J Lipid Res; 2007 Dec; 48(12):2693-700. PubMed ID: 17823457
[TBL] [Abstract][Full Text] [Related]
17. Pectin Penta-Oligogalacturonide Suppresses Intestinal Bile Acids Absorption and Downregulates the FXR-FGF15 Axis in High-Cholesterol Fed Mice.
Zhu R; Hou Y; Sun Y; Li T; Fan J; Chen G; Wei J
Lipids; 2017 Jun; 52(6):489-498. PubMed ID: 28474246
[TBL] [Abstract][Full Text] [Related]
18. FGF21 protects against hepatic lipotoxicity and macrophage activation to attenuate fibrogenesis in nonalcoholic steatohepatitis.
Liu C; Schönke M; Spoorenberg B; Lambooij JM; van der Zande HJP; Zhou E; Tushuizen ME; Andreasson AC; Park A; Oldham S; Uhrbom M; Ahlstedt I; Ikeda Y; Wallenius K; Peng XR; Guigas B; Boon MR; Wang Y; Rensen PCN
Elife; 2023 Jan; 12():. PubMed ID: 36648330
[TBL] [Abstract][Full Text] [Related]
19. Impact of Inhibiting Ileal Apical versus Basolateral Bile Acid Transport on Cholesterol Metabolism and Atherosclerosis in Mice.
Dawson PA
Dig Dis; 2015; 33(3):382-7. PubMed ID: 26045273
[TBL] [Abstract][Full Text] [Related]
20. Combined inhibition of bile salt synthesis and intestinal uptake reduces cholestatic liver damage and colonic bile salts in mice.
Kunst RF; Bolt I; van Dasselaar RDJ; Nijmeijer BA; Beuers U; Oude Elferink RPJ; van de Graaf SFJ
JHEP Rep; 2024 Jan; 6(1):100917. PubMed ID: 38074508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
